Methicillin-resistant Staphylococcus aureus virulence and regulatory proteins

Methicillin-resistant Staphylococcus aureus (MRSA) virulence and regulatory proteins constitute a broad class of therapeutic targets involved in the pathogenesis and environmental adaptation of the bacterium [1, 5]. These include global regulatory systems such as the Accessory Gene Regulator (Agr) and Staphylococcal Accessory Regulator (SarA), which coordinate the expression of a vast array of toxins and enzymes through quorum sensing and transcriptional modulation [7, 8]. Other key targets within this category are secreted toxins like Alpha-hemolysin (Hla) and Panton-Valentine Leukocidin (PVL), as well as surface-anchoring enzymes like Sortase A and nutrient acquisition systems like MntABC [1, 5, 10]. Drugs targeting these proteins, such as the monoclonal antibody Suvratoxumab or the small molecule Savarin, aim to attenuate the pathogen's ability to cause tissue damage and evade the host immune system without directly killing the bacteria [7, 10]. This anti-virulence approach is designed to reduce the selective pressure for antibiotic resistance and is typically intended for use as an adjunctive therapy alongside traditional bactericidal antibiotics [5, 7]. By disarming the pathogen, these therapies can potentially improve outcomes in severe MRSA-mediated conditions like pneumonia, bacteremia, and skin infections [2, 4].

Other names

Staphylococcal virulence factorsMRSA global regulatorsStaphylococcus aureus virulence determinantsAnti-virulence targetsStaphylococcal accessory regulators

Inhibition of quorum sensing (quorum quenching), inhibition of global transcriptional regulators (e.g., AgrA, SarA, MgrA), neutralization of secreted toxins, and inhibition of surface protein anchoring enzymes.